Literature DB >> 19412187

Spondyloarthropathies: Targeted therapy for psoriatic arthritis.

Dafna D Gladman1.   

Abstract

Tumor necrosis factor inhibitors are an effective treatment for psoriatic arthritis, but no single agent is effective in all patients. Novel therapies that target other cytokines have now been tested, with encouraging results.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19412187     DOI： 10.1038/nrrheum.2009.76

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  10 in total

Review 1.  Therapies for peripheral joint disease in psoriatic arthritis. A systematic review.

Authors:  Enrique R Soriano; Neil J McHugh
Journal:  J Rheumatol       Date:  2006-05-15       Impact factor: 4.666

2.  Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis.

Authors:  Ulrike Hüffmeier; Jesús Lascorz; Beate Böhm; Jörg Lohmann; Jörg Wendler; Rotraut Mössner; Kristian Reich; Heiko Traupe; Werner Kurrat; Harald Burkhardt; André Reis
Journal:  J Invest Dermatol       Date:  2008-09-18       Impact factor: 8.551

3.  Increased synovial fluid levels of interleukin-12, sCD25 and sTNF-RII/sTNF-RI ratio delineate a cytokine pattern characteristic of immune arthropathies.

Authors:  C Ribbens; B André; O Kaye; M J Kaiser; V Bonnet; D de Groote; N Franchimont; M G Malaise
Journal:  Eur Cytokine Netw       Date:  2000-12       Impact factor: 2.737

Review 4.  A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis.

Authors:  V Ravindran; D L Scott; E H Choy
Journal:  Ann Rheum Dis       Date:  2007-09-07       Impact factor: 19.103

5.  Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

Authors:  Alice Gottlieb; Alan Menter; Alan Mendelsohn; Yaung-Kaung Shen; Shu Li; Cynthia Guzzo; Scott Fretzin; Rod Kunynetz; Arthur Kavanaugh
Journal:  Lancet       Date:  2009-02-11       Impact factor: 79.321

6.  Association of interleukin 23 receptor variants with psoriatic arthritis.

Authors:  Proton Rahman; Robert D Inman; Walter P Maksymowych; Jeff P Reeve; Lynette Peddle; Dafna D Gladman
Journal:  J Rheumatol       Date:  2009-01       Impact factor: 4.666

7.  A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.

Authors:  Gerald G Krueger; Richard G Langley; Craig Leonardi; Newman Yeilding; Cynthia Guzzo; Yuhua Wang; Lisa T Dooley; Mark Lebwohl
Journal:  N Engl J Med       Date:  2007-02-08       Impact factor: 91.245

Review 8.  Immune regulation in psoriasis and psoriatic arthritis--recent developments.

Authors:  Axel J Hueber; Iain B McInnes
Journal:  Immunol Lett       Date:  2007-09-25       Impact factor: 3.685

Review 9.  Psoriatic arthritis.

Authors:  Dafna D Gladman
Journal:  Dermatol Ther       Date:  2009 Jan-Feb       Impact factor: 2.851

10.  Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways.

Authors:  Rajan P Nair; Kristina Callis Duffin; Cynthia Helms; Jun Ding; Philip E Stuart; David Goldgar; Johann E Gudjonsson; Yun Li; Trilokraj Tejasvi; Bing-Jian Feng; Andreas Ruether; Stefan Schreiber; Michael Weichenthal; Dafna Gladman; Proton Rahman; Steven J Schrodi; Sampath Prahalad; Stephen L Guthery; Judith Fischer; Wilson Liao; Pui-Yan Kwok; Alan Menter; G Mark Lathrop; Carol A Wise; Ann B Begovich; John J Voorhees; James T Elder; Gerald G Krueger; Anne M Bowcock; Gonçalo R Abecasis
Journal:  Nat Genet       Date:  2009-01-25       Impact factor: 38.330
  10 in total
  1 in total

Review 1.  Psoriatic arthritis in South and Central America.

Authors:  Sergio M A Toloza; Rafael Valle-Oñate; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2011-08       Impact factor: 4.592
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.